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Abstract
Relaxin family peptide receptors (RXFP, nomenclature as agreed by the NC-IUPHAR Subcommittee on
Relaxin family peptide receptors [18, 75]) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous
agonists at these receptors are heterodimeric peptide hormones structurally related to insulin: relaxin-1, relaxin,
relaxin-3 (also known as INSL7), insulin-like peptide 3 (INSL3) and INSL5. Species homologues of relaxin have
distinct pharmacology and relaxin interacts with RXFP1, RXFP2 and RXFP3, whereas mouse and rat relaxin
selectively bind to and activate RXFP1 [172]. relaxin-3 is the ligand for RXFP3 but it also binds to RXFP1 and
RXFP4 and has differential affinity for RXFP2 between species [170]. INSL5 is the ligand for RXFP4 but is a
weak antagonist of RXFP3. relaxin and INSL3 have multiple complex binding interactions with RXFP1 [176] and
RXFP2 [84] which direct the N-terminal LDLa modules of the receptors together with a linker domain to act as a
tethered ligand to direct receptor signaling [173]. INSL5 and relaxin-3 interact with their receptors using distinct
residues in their B-chains for binding, and activation, respectively [211, 97].
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